biotech / news / / The Irish Times
Pfizer's first-quarter beat of Wall Street expectations on sales and profit.
Eliquis sales grew 13% year-over-year and now represent 15% of Pfizer's total revenue.
KEY POINTS
- Eliquis, Ibrance, and Prevnar 13 all face key patent expirations within the next two years.
- Vyndamax, recently switched from Vyndaqel, secured patent protection until 2031 after settlements with generics producers.
- Pfizer's first obesity drug from the $10B Metsera acquisition is not expected before 2028.
- Recent launches and acquisitions drove 22% revenue growth, but the upcoming patent cliff remains a serious threat.
COMPANIES
Summarized by Newsio from The Irish Times. How we summarize →